The Effect of Guidance regarding Home Exercise and ADL on Adolescent Females Suffering from Adverse Effects after HPV Vaccination in Japanese Multidisciplinary Pain Centers

Table 1

Patients’ characteristics.

	Accept	Decline
Age (years), median (range)	15 (12–19)	16 (12–19)	0.0766
Vaccine, (%)			0.1443
Quadrivalent	33 (31.4)	9 (25.0)
Bivalent	69 (65.7)	27 (65.0)
Unknown	3 (2.8)	4 (10.0)
Vaccine doses, (%)			0.9366
3 doses	77 (73.3)	31 (77.5)
2 doses	17 (16.2)	5 (12.5)
1 dose	9 (8.6)	3 (7.5)
Unknown	2 (1.9)	1 (2.5)
Onset			0.5483
After first vaccination, (%)	9 (8.6)	2 (5.0)
Onset interval (days), median (range)	0 (0–21)	10 (9–11)
After second vaccination, (%)	13 (12.4)	7 (17.5)
Onset interval (days), median (range)	1 (0–90)	9 (0–90)
After third vaccination, (%)	65 (61.9)	22 (55.0)
Onset interval (days), median (range)	30 (0–1230)	105 (1–690)
Duration of symptom (months), median (range)	12 (1–48)	18 (2–37)	0.2839
Pretreatment HADS
Anxiety, median (range)	5 (0–17)	6 (0–15)	0.2140
Depression, median (range)	4 (0–16)	5 (0–16)	0.2409
Pretreatment PCS, median (range)	27.5 (0–51)	30 (0–52)	0.8238
Pretreatment NRS of pain, median (range)	5 (0–10)	4 (0–7)	0.0207

HADS, Hospital Anxiety and Depression Scale. PCS, Pain Catastrophizing Scale. NRS, numerical rating scale. Significant difference.